SPL13 Antibody

What is SPL13 and why is it important in plant biology research?

SPL13 (Squamosa Promoter-Binding-Like protein 13A) is a transcription factor belonging to the SBP-Box gene family. It plays critical roles in regulating plant architecture and development. In tomato (Solanum lycopersicum), SPL13 has been identified as a key regulator of inflorescence structure, lateral branch development, and flower/fruit production . Research has demonstrated that SPL13 is targeted by microRNA miR156a, which suppresses its expression to control plant development .

SPL13 functions by directly binding to promoter regions of genes like SINGLE FLOWER TRUSS (SFT), thereby positively regulating their expression and influencing inflorescence development . Recent studies have also revealed that SPL13 controls root apical meristem phase changes by triggering oriented cell divisions , and mediates strigolactone suppression of shoot branching by inhibiting cytokinin synthesis . This multifaceted regulatory role makes SPL13 an important research target for understanding plant development mechanisms and potentially improving crop yield through genetic engineering.

What validation strategies should be implemented before using an SPL13 antibody in research?

Validation of SPL13 antibodies requires a multi-faceted approach to ensure specificity, selectivity, and reproducibility:

• Genetic verification (gold standard):

  • Test antibodies against CRISPR-Cas9 generated SPL13 knockout samples

  • Compare with SPL13 RNAi knockdown tissues

  • Loss of signal in knockout samples strongly indicates antibody specificity

• Multiple cell/tissue line testing:

  • Evaluate antibody performance across different plant tissues or cell types

  • Compare expression patterns with known transcriptomic data

• Western blot validation:

  • Determine if observed molecular weight matches predicted SPL13 size

  • Check for single, clean bands at expected size

  • Confirm absence of significant off-target binding

The evidence supporting a properly validated antibody should include documentation of these approaches along with experimental details that demonstrate reproducible results within and between Western blotting experiments .

What is the appropriate protocol for using SPL13 antibodies in Western blot analyses?

For optimal Western blot analysis using SPL13 antibodies, follow this detailed protocol:

Sample preparation:

• Extract total protein from plant tissues using a buffer containing protease inhibitors

• Determine protein concentration using Bradford or BCA assay

• Prepare samples by mixing with Laemmli buffer and denaturing at 95°C for 5 minutes

• Load 20-40 μg of protein per lane alongside molecular weight markers

Electrophoresis and transfer:

• Separate proteins using 10-12% SDS-PAGE gel (appropriate for transcription factors)

• Transfer to PVDF or nitrocellulose membrane at 100V for 1 hour or 30V overnight at 4°C

• Verify transfer efficiency with reversible staining (Ponceau S)

Immunoblotting:

• Block membrane with 5% non-fat dry milk or 3-5% BSA in TBST for 1 hour at room temperature

• Incubate with primary SPL13 antibody at optimized dilution (typically 1:1000) overnight at 4°C

• Wash 3-5 times with TBST, 5-10 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour

• Wash 3-5 times with TBST, 5-10 minutes each

• Develop using chemiluminescent substrate and image with appropriate system

Critical controls:

• Positive control: Tissue known to express SPL13 (e.g., wild-type samples)

• Negative control: SPL13 knockout/knockdown samples

• Loading control: Housekeeping protein (e.g., Actin, GAPDH, Histone H3)

• Isotype control: Same concentration of irrelevant antibody of same isotype

For quantitative analysis, ensure imaging is performed within the linear range of detection and normalize SPL13 signal to loading control .

How can SPL13 antibodies be used to investigate DNA-protein interactions?

SPL13 antibodies can be employed to study DNA-protein interactions through several advanced techniques:

Chromatin Immunoprecipitation (ChIP):

• Cross-link proteins to DNA in plant tissues using 1% formaldehyde for 10-15 minutes

• Extract chromatin and fragment by sonication to 200-500 bp fragments

• Immunoprecipitate SPL13-DNA complexes using validated SPL13 antibody

• Reverse cross-links and purify DNA

• Analyze by qPCR targeting suspected binding regions (e.g., SFT promoter) or perform genome-wide analysis via ChIP-seq

For ChIP experiments examining SPL13 binding, the appropriate controls are essential:

• Input DNA (pre-immunoprecipitation sample)

• Non-specific IgG antibody control

• Positive control region (known SPL13 binding site)

• Negative control region (non-target genomic locus)

Electrophoretic Mobility Shift Assay (EMSA) with supershift:

• Prepare nuclear extracts from plant tissues

• Incubate labeled DNA probe containing suspected SPL13 binding motif with extract

• Add SPL13 antibody to create a "supershift" that confirms SPL13 in the complex

• Analyze by native PAGE to visualize shifted and supershifted complexes

Based on published research, SPL13 has been demonstrated to directly bind promoter regions of genes including SFT, IPT1, CCD7, and MAX1, controlling various aspects of plant development and architecture .

How do you optimize immunofluorescence protocols for detecting nuclear-localized SPL13?

Optimizing immunofluorescence protocols for nuclear-localized SPL13 requires special consideration:

Sample preparation and fixation:

• Fix plant tissues or cells with 4% paraformaldehyde for 20-30 minutes

• Embed in optimal cutting temperature compound and prepare thin sections (5-10 μm)

• For enhanced nuclear protein detection, consider a dual fixation approach using both paraformaldehyde and methanol

Antigen retrieval (critical for nuclear proteins):

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) at 95°C for 10-20 minutes

• Cool gradually to room temperature

• This step is essential as nuclear proteins may have epitopes masked by fixation or chromatin structure

Permeabilization and blocking:

• Permeabilize with 0.5% Triton X-100 for 10-15 minutes (critical for nuclear protein access)

• Block with 5% normal serum (matching secondary antibody host) with 1% BSA for 1 hour

Antibody incubation:

• Apply optimized dilution of primary SPL13 antibody (typically 1:100-1:500) overnight at 4°C

• Wash extensively with PBS-T (3-5 times, 5-10 minutes each)

• Incubate with fluorophore-conjugated secondary antibody (1:200-1:500) for 1-2 hours at room temperature

• Counterstain nuclei with DAPI (1 μg/ml) for 5-10 minutes

Controls and validation:

• Include SPL13 knockout samples as negative controls

• Perform a primary antibody omission control

• Include nuclear marker (e.g., histone protein) as co-staining reference

According to published research, SPL13 shows exclusive nuclear localization consistent with its function as a transcription factor . When optimizing, test multiple antibody dilutions and incubation times to determine optimal signal-to-noise ratio for your specific samples.

What approaches can be used to study SPL13 regulation by miR156a using antibody-based techniques?

Studying the regulation of SPL13 by miR156a requires several antibody-based approaches:

Western blot analysis for protein level comparison:

• Compare SPL13 protein levels between:

  • Wild-type plants and miR156a overexpression (35S-miR156a) plants

  • Plants expressing wild-type SPL13 vs. miR156a-resistant SPL13 variant

• Extract total protein from comparable tissues and developmental stages

• Perform Western blot using validated SPL13 antibody

• Quantify SPL13 levels normalized to loading controls

Research has demonstrated that miR156a overexpression significantly reduces SPL13 protein levels, confirming post-transcriptional regulation .

Heterologous expression systems to validate regulation:

• Co-express SPL13-FLAG with empty vector or miR156a-expressing vector in N. benthamiana

• Extract protein after 48-72 hours

• Detect SPL13-FLAG protein using anti-FLAG antibody

• Quantify reduction in SPL13 protein levels when co-expressed with miR156a

Published data shows that SPL13-FLAG accumulates to significantly lower levels when co-expressed with miR156a compared to empty vector control .

Validation with miR156-resistant SPL13:

• Create SPL13 construct with mutations in the miR156a recognition site without altering amino acid sequence

• Express in 35S-miR156a background

• Analyze SPL13 protein levels by Western blot

• Assess phenotypic rescue as functional validation

This experimental design provides strong evidence for direct regulation, as shown in studies where expression of miR156-resistant SPL13 in miR156a-overexpressing plants reversed the branching phenotype .

How can researchers distinguish between SPL13A and SPL13B when using commercial antibodies?

Distinguishing between the highly similar SPL13A and SPL13B proteins requires careful antibody selection and validation:

Understanding antibody cross-reactivity:
According to product information, some commercial SPL13A antibodies show 100% sequence homology with SPL13B (AT5G50670), making distinction challenging . Researchers should:

• Carefully review antibody specificity information provided by manufacturer

• Check the immunogen sequence used for antibody production

• Determine if the antibody was raised against a region common to both isoforms or unique to one

Experimental approaches for distinction:

• Genetic validation:

  • Test antibody against SPL13A-specific and SPL13B-specific knockout lines

  • Use isoform-specific RNAi lines to verify differential detection

• Peptide competition assay:

  • Pre-incubate antibody with SPL13A-specific and SPL13B-specific peptides separately

  • If signal is blocked only by SPL13A peptide, the antibody is likely specific to that isoform

• Immunoprecipitation with mass spectrometry:

  • Perform IP using the antibody

  • Analyze precipitated proteins by mass spectrometry to identify isoform-specific peptides

When absolute specificity is required, consider using epitope-tagged versions of SPL13A and SPL13B and detecting with anti-tag antibodies as an alternative approach.

What are the common causes of false positives/negatives when using SPL13 antibodies, and how can they be addressed?

Understanding and addressing false results is critical for reliable SPL13 antibody-based experiments:

Common causes of false positives:

• Cross-reactivity with related proteins:

  • SPL family contains multiple members with conserved domains

  • Solution: Validate antibody specificity using knockout controls or peptide competition

  • Consider using antibodies targeting less conserved regions of SPL13

• Non-specific binding:

  • Inadequate blocking or excessive antibody concentration

  • Solution: Optimize blocking conditions (test different blocking agents like BSA, milk, commercial blockers)

  • Titrate antibody concentration to minimize background

• Secondary antibody issues:

  • Non-specific binding of secondary antibody

  • Solution: Include secondary-only control, use species-appropriate secondary antibodies

  • Pre-adsorb secondary antibodies against plant proteins if working with plant tissues

Common causes of false negatives:

• Epitope masking:

  • Post-translational modifications or protein-protein interactions blocking antibody access

  • Solution: Try different extraction conditions or denaturation methods

  • Test antibodies targeting different epitopes of SPL13

• Degradation during sample preparation:

  • Proteolytic degradation of SPL13 during extraction

  • Solution: Use fresh protease inhibitors, keep samples cold, minimize processing time

  • Consider alternative extraction buffers optimized for nuclear proteins

• Insufficient antigen retrieval (for immunohistochemistry):

  • Nuclear proteins often require robust antigen retrieval

  • Solution: Optimize antigen retrieval methods (heat, pH, enzymatic) for SPL13 detection

  • Test multiple retrieval protocols to determine optimal conditions

Systematic troubleshooting approach:

• Run appropriate positive and negative controls with each experiment

• Include isotype controls to assess non-specific binding

• When possible, validate findings using complementary techniques (e.g., RNA analysis)

How should researchers evaluate batch-to-batch variability in commercial SPL13 antibodies?

Batch-to-batch variability in commercial antibodies is a significant concern that can impact experimental reproducibility. Here's a systematic approach to evaluate and manage this variability:

Initial batch validation:

• Request lot-specific validation data from the manufacturer

• Perform side-by-side comparison with previous batch using identical samples and protocols

• Document key performance metrics:

  • Signal intensity at standardized exposure

  • Signal-to-noise ratio

  • Background levels

  • Detection limit

  • Band pattern/specificity profile

Quantitative assessment protocol:

• Prepare a standard curve using recombinant SPL13 or consistent positive control samples

• Test both old and new antibody batches against this standard curve

• Calculate and compare:

  • EC50 values (concentration giving half-maximal signal)

  • Linear dynamic range

  • Coefficient of variation between replicates

Documentation and quality control:

• Create a validation report for each new batch containing:

  • Lot number and acquisition date

  • Performance metrics compared to previous batch(es)

  • Images of side-by-side Western blots

  • Optimized working dilution for new batch

• Maintain a laboratory antibody database with:

  • Performance history of each batch

  • Optimal conditions for each application

  • Observed variability between batches

If significant variability is detected, consider:

• Re-optimizing working dilutions and conditions for the new batch

• Acquiring a larger quantity of a well-performing batch

• Switching to recombinant antibodies when available, which typically show less batch variability

How can SPL13 antibodies be used to investigate the interplay between strigolactone signaling and cytokinin synthesis?

Recent research has identified SPL13 as a mediator between strigolactone signaling and cytokinin synthesis in tomato, making antibody-based approaches valuable for investigating this regulatory network:

Co-immunoprecipitation experiments:

• Treat plant samples with strigolactone analog GR24 or vehicle control

• Perform immunoprecipitation using SPL13 antibody

• Analyze co-precipitated proteins by mass spectrometry or Western blot

• Look for strigolactone signaling components or cytokinin synthesis regulators

Chromatin immunoprecipitation (ChIP) to identify direct targets:

• Treat plants with GR24 or control

• Perform ChIP using SPL13 antibody

• Analyze DNA enrichment at promoters of cytokinin synthesis genes (e.g., IPT1) and strigolactone synthesis genes (CCD7, MAX1)

• Quantify binding changes in response to hormone treatment

Research has demonstrated that SPL13 directly represses the transcription of IPT1 (cytokinin synthesis) and the strigolactone synthesis genes CCD7 and MAX1, creating a regulatory feedback loop . This suggests SPL13 acts as a critical node in hormonal crosstalk controlling plant architecture.

Experimental design for hormone response studies:

• Compare SPL13 protein levels, phosphorylation state, and nuclear localization between:

  • Wild-type plants

  • Strigolactone-deficient mutants (e.g., ccd mutants)

  • GR24-treated plants

• Use Western blot with SPL13 antibody to detect total protein

• Use phospho-specific antibodies (if available) or phosphoprotein staining to assess modification status

• Correlate changes with cytokinin levels and branching phenotypes

This experimental approach can elucidate the molecular mechanisms by which strigolactone regulates SPL13 function to control branching.

What strategies can overcome epitope masking issues when detecting SPL13 in different experimental contexts?

Epitope masking is a common challenge when detecting nuclear transcription factors like SPL13. Here are strategies to overcome this issue:

Understanding potential masking mechanisms for SPL13:

• Protein-protein interactions: SPL13 likely functions in multi-protein complexes

• DNA binding: The SBP domain may be occupied when bound to DNA

• Post-translational modifications: Phosphorylation or other modifications may alter epitope accessibility

• Conformational changes: Different cellular conditions may induce structural changes

Optimization strategies for Western blotting:

• Sample preparation modifications:

  • Test multiple extraction buffers with varying salt concentrations (150-500 mM NaCl)

  • Compare denaturing vs. native extraction conditions

  • Try different detergents (SDS, NP-40, Triton X-100) at various concentrations

  • Add DNase I treatment to disrupt DNA-protein interactions

• Denaturation optimization:

  • Test different denaturation temperatures (37°C, 70°C, 95°C)

  • Vary denaturation time (5-30 minutes)

  • Try reducing agents at different concentrations (DTT, β-mercaptoethanol)

  • For membrane-associated proteins, consider sonication or freeze-thaw cycles

Immunohistochemistry/immunofluorescence approaches:

• Antigen retrieval methods comparison:

  • Heat-induced epitope retrieval (microwave, pressure cooker, water bath)

  • pH optimization (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Enzymatic retrieval (proteinase K, trypsin)

  • Combined approaches for difficult epitopes

• Fixation optimization:

  • Compare cross-linking fixatives (paraformaldehyde) vs. precipitating fixatives (methanol/acetone)

  • Test fixation duration (10-30 minutes)

  • Try post-fixation treatments to enhance epitope accessibility

Alternative detection strategies:

• Use multiple antibodies targeting different epitopes of SPL13

• Consider epitope-tagged SPL13 expression when genetic manipulation is possible

• For difficult samples, try protein arrays or proximity ligation assays

These approaches systematically address the various mechanisms that might cause epitope masking in SPL13 detection across different experimental contexts.

How can researchers quantitatively analyze SPL13 expression changes in developmental studies?

Quantitative analysis of SPL13 expression throughout development requires rigorous methodology:

Western blot quantification:

• Design a time-course or developmental stage-specific sampling strategy

• Ensure consistent protein extraction efficiency across developmental stages

• Load equal amounts of total protein (20-40 μg) verified by total protein staining

• Include recombinant SPL13 standards if absolute quantification is needed

• Use digital imaging systems (not film) for quantitative Western blot

• Ensure signal is within linear dynamic range of detection

• Normalize SPL13 signal to appropriate loading controls

Statistical analysis approach:

• Perform at least 3 biological replicates per developmental stage

• Calculate relative expression levels (normalized to loading control)

• Apply appropriate statistical tests for time-course data (repeated measures ANOVA)

• Use post-hoc tests (Tukey's HSD, Bonferroni) for multiple comparisons

• Present data as mean ± standard error with significance indicators

Complementary methods for validation:

• Correlate protein levels with transcript levels using RT-qPCR

• Perform immunohistochemistry to assess tissue-specific expression patterns

• Consider mass spectrometry-based quantification for highest precision

Advanced quantitative imaging approach:

• Use immunofluorescence with SPL13 antibody across developmental stages

• Capture images using identical microscope settings

• Quantify nuclear fluorescence intensity using software like ImageJ

• Normalize to nuclear area or DAPI staining

• Analyze large numbers of cells (>100 per sample) for statistical robustness

This multi-pronged quantitative approach can reveal developmental dynamics of SPL13 expression, providing insights into its regulatory role during plant development.

How can SPL13 antibodies be integrated with new techniques like single-cell protein analysis in plant tissues?

Integrating SPL13 antibodies with cutting-edge single-cell techniques represents an emerging frontier in plant biology research:

Single-cell protein analysis approaches:

• Mass cytometry (CyTOF) adaptation for plant tissues:

  • Conjugate SPL13 antibodies with rare earth metal isotopes

  • Develop plant tissue dissociation protocols preserving protein epitopes

  • Create panel with other plant development markers

  • Analyze protein co-expression at single-cell resolution

  • Challenge: Requires optimization of cell wall digestion while preserving nuclear proteins

• Imaging mass cytometry for spatial analysis:

  • Apply metal-tagged SPL13 antibodies to tissue sections

  • Laser ablation coupled with mass spectrometry enables spatial resolution

  • Multiplex with markers for cell types, cell cycle, and hormone response

  • Advantage: Maintains tissue architecture while providing single-cell data

• Proximity ligation assay (PLA) for protein interaction studies:

  • Use SPL13 antibody paired with antibodies against potential interaction partners

  • Detect protein-protein interactions in situ at single-cell level

  • Quantify interaction differences between cell types or developmental stages

  • Particularly valuable for studying SPL13 interactions with other transcription factors

• Microfluidic antibody-based single-cell Western blotting:

  • Isolate individual plant cells in microfluidic chambers

  • Perform lysis, electrophoresis, and immunoblotting in miniaturized format

  • Detect SPL13 and other proteins in single cells

  • Challenge: Adaptation of existing mammalian protocols to plant cells

Implementation considerations:

• Antibody validation becomes even more critical at single-cell level

• Consider using recombinant antibody fragments (Fab, scFv) for better tissue penetration

• Develop spike-in controls for quantification standardization

• Establish computational pipelines for single-cell protein data analysis

These approaches can reveal cell-type specific expression patterns and regulatory mechanisms of SPL13 that may be masked in whole-tissue analyses.

What are the best methods for multiplexed detection of SPL13 and other transcription factors in the same sample?

Multiplexed detection of SPL13 alongside other transcription factors provides valuable insights into regulatory networks but presents technical challenges:

Multiplexed immunofluorescence approaches:

• Sequential immunostaining:

  • Apply primary antibody for SPL13, followed by fluorophore-conjugated secondary

  • Strip or inactivate antibodies using glycine-HCl (pH 2.5), SDS, or heat

  • Repeat with antibodies against other transcription factors

  • Advantage: Can use antibodies from the same species

  • Challenge: Epitope degradation with multiple stripping cycles

• Spectral unmixing:

  • Use primary antibodies from different species

  • Apply spectrally distinct fluorophore-conjugated secondary antibodies

  • Image with spectral detector

  • Apply computational unmixing to separate overlapping fluorophore spectra

  • Can typically resolve 4-7 different proteins simultaneously

• Tyramide signal amplification (TSA):

  • Use HRP-conjugated secondary antibodies sequentially

  • Deposit tyramide-fluorophores that covalently bind to sample

  • Inactivate HRP between cycles

  • Can detect up to 10 proteins on the same sample

  • Particularly useful for low-abundance transcription factors

Multiplexed protein detection in Western blots:

• Multi-color fluorescent Western blotting:

  • Use primary antibodies from different host species

  • Apply fluorescently-labeled secondary antibodies with distinct emission spectra

  • Image using multi-channel fluorescence scanners

  • Can typically detect 3-4 proteins simultaneously

  • Use appropriate controls to ensure no cross-reactivity between detection systems

• Sequential reprobing:

  • After detection of SPL13, strip antibodies using commercial stripping buffer

  • Verify complete stripping by incubating with secondary antibody only

  • Reprobe with antibody against different transcription factor

  • Document each round of detection separately

Advanced multiplex approaches:

• Mass spectrometry-based multiplexing:

  • Immunoprecipitate using SPL13 antibody

  • Analyze co-precipitated proteins by mass spectrometry

  • Can detect hundreds of interacting proteins simultaneously

  • Provides unbiased identification of SPL13 interaction partners

• Microfluidic antibody microarrays:

  • Spot multiple antibodies in microfluidic channels

  • Flow cell lysate over array

  • Detect bound proteins with labeled detection antibodies

  • Can analyze dozens of proteins from limited sample amounts

These multiplexed approaches enable comprehensive analysis of transcription factor networks including SPL13, providing insights into complex regulatory mechanisms in plant development.

How can machine learning be integrated with SPL13 antibody-based imaging for high-throughput phenotyping?

Integrating machine learning with SPL13 antibody-based imaging creates opportunities for automated, high-throughput phenotypic analysis:

Image acquisition and preprocessing:

• Establish standardized immunofluorescence protocols for SPL13 detection

• Develop automated microscopy workflows for high-content imaging

• Create preprocessing pipelines for:

  • Image normalization and background correction

  • Channel alignment and registration

  • Cell segmentation (identifying individual cells)

  • Feature extraction (intensity, texture, morphology)

Machine learning applications for SPL13 imaging:

• Cell classification and phenotyping:

  • Train convolutional neural networks (CNNs) to classify cell types based on SPL13 expression patterns

  • Develop algorithms to quantify nuclear localization and intensity

  • Create phenotypic profiles based on SPL13 distribution patterns

  • Applications: Identify cellular subtypes in developmental contexts, quantify responses to treatments

• Tissue-level pattern recognition:

  • Apply deep learning to recognize spatial patterns of SPL13 expression

  • Identify developmental transitions or responses to environmental stimuli

  • Create tissue-level maps of transcription factor activity

  • Advantage: Captures emergent properties not visible at single-cell level

• Multiparameter correlation analysis:

  • Integrate SPL13 data with other cellular markers

  • Use dimension reduction techniques (PCA, t-SNE, UMAP) to visualize relationships

  • Identify correlated expression patterns and potential regulatory networks

  • Applications: Discover novel interactions and regulatory relationships

Implementation strategy:

• Data collection and training:

  • Generate large annotated datasets of SPL13 immunofluorescence images

  • Include diverse conditions: developmental stages, genetic backgrounds, treatments

  • Manually annotate subset for training (cell boundaries, expression categories)

  • Use data augmentation to enhance training set diversity

• Model development and validation:

  • Train models using frameworks like TensorFlow or PyTorch

  • Validate using held-out test sets and expert evaluation

  • Implement cross-validation to ensure robustness

  • Fine-tune for specific applications

• Deployment in research workflows:

  • Create user-friendly interfaces for non-computational biologists

  • Implement batch processing for high-throughput applications

  • Develop methods to integrate results with other experimental data

  • Establish protocols for model maintenance and updating

This integration of machine learning with SPL13 antibody imaging can dramatically accelerate phenotypic analysis, enabling large-scale studies of SPL13 function across diverse conditions and genetic backgrounds.